FDA approves Teva’s Weltruza, a once-monthly subcutaneous olanzapine for schizophrenia whose copolymer depot eliminates post-injection monitoring.
News|Articles|November 20, 2014
Vetter Opens New Office in Singapore to Support Growing Asian Market
Author(s)Pharmaceutical Technology Editors
CDMO Vetter has opened a new representative office in Singapore in response to growing market demand in Asia.
Advertisement
CDMO Vetter, a specialist in aseptic fill and finish of injection systems for the bio/pharmaceutical industry, has opened a new representative office in Singapore in response to growing market demand in Asia. The announcement was made at a ceremony attended by members of local government agencies, a number of executives of pharmaceutical/biotech companies in the Asian region, and Vetter executives.
The new office, headed by Chervee Ho, director, Key Account Management, Asia Pacific, will enable the company to better serve the Asian market, which was previously handled by Vetter’s German-based departments.
Source:
Advertisement
Related to this article
Equivalence test using two one-sided tests are widely used for demonstrating the comparability of treatment effects in different research fields. The method described in the manuscript aims to use simulations in Microsoft Excel to compute power for 2 one-sided tests for two groups with unequal variances.
Richard Jaenisch examines whether FDA's NAM pathway truly shortens drug pipelines or just shifts the evidentiary burden elsewhere.
Susan J. Schniepp, distinguished fellow with Nelson Labs, and Siegfried Schmitt, PhD, vice president, Technical, with Parexel, clear up some of the confusion about what does and does not need to be complied with regarding standards set by international pharmacopoeias.
Mitigating nitrosamine risk requires assessing each product individually, says Bram Baert, Global Head of Regulatory Affairs at Capsugel, and Sandrine Picco, Senior Analytical Specialist on Capsugel's Innovaform Accelerator Team, in this interview with PharmTech.
Jason Bertola, executive director of Commercial Development for the Advanced Synthesis Platform at Lonza in North America, explains the demand for spray drying and the hurdles involved with scale up, in an interview with PharmTech.
API-gated journals may skew pharma regulatory research as AI agents favor accessible sources, raising citation integrity and pharmacovigilance risks.
The FDA has approved remibrutinib for symptomatic dermographism, the first such therapy, extending an oral BTK inhibitor label via the Phase III RemIND trial.
Advertisement
Advertisement
Trending on Pharmaceutical Technology
1
Can Continuous Tableting End Scale-Up for Complex Oral Drugs?
2
Manufacturing Intelligence: Organoids, Organ-on-a-Chip, and the Trust Gap
3
CPHI Milan 2026: Nitrosamine Risk Mitigation, Part 1
4
PharmTech AI Pulse Check: On-Prem vs. Cloud AI
5